OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

Sabatolimab

aka MBG453

Sabatolimab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.